comprehensive -WSS

comprehensive

author：explore 2025-09-05 03:01:46 - browse：4

What difference does a day make? Who gets to have gene therapy? And are biotech startups OK?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere.

For more on what we cover, here’s the story on gene therapy; here’s more on Ipsen’s treatment for FOP; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Biotech companies concerned about China biosecurity crackdown

leisure time

WSS

Scientists unlock the key to scar

How to fix the rural physician shortage in the U.S.

July 4th fireworks can be stressful for dogs. These 6 tips can keep them calm and safe

How to fix the rural physician shortage in the U.S.

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Pfizer highlights cancer drugs it thinks could reignite investor interest

entertainment

comprehensive

entertainment

Supreme Court strikes down use of affirmative action

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Medicare proposal to cover medical devices draws a mixed reaction

Congress gives doctors Medicare pay bump

New air purifier tech could be key to improving indoor air quality

Covid isolation guidance eased by the CDC

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Hepatitis C has a cure — but many Americans still lack access to it

FDA does about

focus

ALS groups 'won't be played again' by the FDA, drug sponsors

Pfizer highlights cancer drugs it thinks could reignite investor interest

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

AstraZeneca loses challenge to Medicare drug price negotiation

hotspot

leisure time

focus

focus